Related Experiment Video
Updated: May 8, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Recombinant activated factor VII administration after pulmonary embolectomy: case report
Nedal Omran1, Jan Harrer, Miroslav Brtko
1Department of Cardiac Surgery, Charles University in Prague, Hradec Kralove, Czech Republic. nidal81@gmail.com
Recombinant activated factor VII (rFVIIa) can manage severe bleeding during pulmonary embolectomy. This case report highlights its rescue use in complex cardiac surgery with coagulopathy.
Area of Science:
- Cardiovascular Surgery
- Hematology
- Anesthesiology
Background:
- Managing coagulopathy during cardiac surgery, especially pulmonary embolectomy, presents significant challenges.
- Recombinant activated factor VII (rFVIIa) is established for postcardiotomy coagulopathy.
- Limited data exists on rFVIIa use in patients with recent thromboembolic events.
Observation:
- A patient undergoing surgical pulmonary embolectomy under cardiopulmonary bypass developed a severe coagulation disorder.
- Standard treatments were insufficient to control the bleeding.
Findings:
- Rescue administration of recombinant activated factor VII (rFVIIa) was successfully employed.
- rFVIIa effectively managed the severe coagulation disorder during the complex procedure.
Implications:
- This case demonstrates the potential utility of rFVIIa as a rescue therapy in challenging bleeding scenarios during cardiac surgery.
- Further research may explore rFVIIa's role in specific coagulopathies associated with thromboembolic events in surgical contexts.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Venous Thrombosis IV: Nursing Management
